Small molecule protein degraders are set to reshape the way by which diseases will be treated.
Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020.
Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.
Our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. Headquartered in Boston with additional laboratory facilities in Basel, Monte Rosa Therapeutics is a private company launched in 2020.
Initially seeded by Versant Ventures and incubated at Ridgeline Discovery in Basel, and The Institute of Cancer Research in London, Monte Rosa has raised $32.5 million from Versant and New Enterprise Associates. Academic co-founders are Prof. Raj Chopra and Prof. Ian Collins of The Institute for Cancer Research, UK.
Location: United States, Massachusetts, Boston
Employees: 51-200
Total raised: $445.5M
Founded date: 2019
Investors 6
| Date | Name | Website |
| 07.08.2021 | New Enterp... | nea.com |
| 31.10.2020 | Aisling Ca... | aislingcap... |
| - | Avoro Capi... | avorocapit... |
| - | Amzak Heal... | amzakhealt... |
| - | HBM Partne... | hbmpartner... |
| 02.10.2020 | GV | gv.com |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 25.06.2021 | IPO | $222M | - |
| 19.03.2021 | Series C | $95M | - |
| 25.09.2020 | Series B | $96M | New Enterp... |
| 27.05.2020 | Series A | $32.5M | New Enterp... |
Mentions in press and media 27
| Date | Title | Description |
| 28.10.2024 | Monte-Rosa Therapeutics enters billion-dollar partnership with Novartis | Monte Rosa Therapeutics is a clinical-stage biotechnology company based in Boston and Basel developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune ... |
| 04.02.2022 | Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences | BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue degrader medicines, today announced that the company is scheduled to present at the following up... |
| 10.11.2021 | Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates | – Initiated Investigational New Drug (IND)-Enabling Activities for MRT-2359, a Molecular Glue Degrader Selectively Targeting GSPT1 – – Presented Preclinical Data at AACR-NCI-EORTC Highlighting the Potential of GSPT1-directed Molecular Glue ... |
| 25.06.2021 | Monte Rosa Therapeutics raises USD222 million in successful IPO | |
| 25.06.2021 | Monte Rosa Therapeutics raises USD222 million in successful IPO | After VectivBio, Gain Therapeutics, Pharvaris and NLS Pharmaceutics, Monte Rosa Therapeutics is already the fifth biotech company with Swiss roots going public on Nasdaq in 2021. Monte Rosa Therapeutics is developing a portfolio of novel sm... |
| 19.03.2021 | Monte Rosa closes $95 million series C round | Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine based in Basel and is active in both Boston and Basel. With the core focus on discovering and developing molecular glues to degrade disease-causing ... |
| 19.03.2021 | Monte Rosa closes $95 million series C round | |
| 16.03.2021 | Monte Rosa Therapeutics Raises $95M in Series C Financing | Monte Rosa Therapeutics, a Boston, MA-based biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, closed a $95m Series C financing. The round was led by Avoro Capital Advisors... |
| 15.03.2021 | Monte Rosa Therapeutics secures $95M | Monte Rosa Therapeutics has raised a $95 million Series C led by Avoro Capital Advisors. The Boston-based company is developing precision medicines designed to target disease-causing proteins. Select Additional Investors Aisling Capital, Ca... |
| 12.03.2021 | Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform | BOSTON, MA – March 12, 2021 – Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today the closing of a $95 million Series C financing.... |
Show more